Biomerica, Inc. reports a 4% decline in operating expenses year-to-date, while the balance sheet strengthens with a 14.7% improvement in working capital. The company expands the commercialization of inFoods® IBS through a collaboration with Henry Schein and launches an AI-backed inFoods® IBS Trigger Food Navigator to support personalized therapy. Additionally, the CMS establishes a national Medicare payment rate for the inFoods® IBS test, and the Egyptian Drug Authority authorizes Biomerica’s complete screening test portfolio. Management emphasizes a strategic pivot towards higher-value products and highlights a 27% reduction in research and development expenses. Net sales for the second quarter were $1.21 million, reflecting a decrease from the prior year due to the absence of large distributor stocking orders in the MENA region. Operating expenses decreased by 4% for the six months ended November 30, 2025, while net loss improved to $1.31 million. Biomerica remains focused on operational efficiency and disciplined cost management to drive long-term value.

Read more at GlobeNewswire: Biomerica Reports Second Quarter Fiscal 2026 Financial